



Vaccine Fact Sheet

DTaP-IPV-Hib-HepB combination vaccine

Brand Name and Manufacturer	VAXELIS™ Merck and Sanofi Pasteur
Protects Against	Diphtheria, tetanus, pertussis, polio, and <i>Haemophilus influenzae</i> type b (Hib) and hepatitis B
Routine Schedule	Three (3) dose series: 2, 4, and 6 months of age
Minimum Intervals	4-week minimum interval between dose 1 and 2 4-week minimum interval between dose 2 and 3
Approved for use in	Children aged 6 weeks through 4 years
Administration	Intramuscular (IM) injection
Packaging	10 single-dose 0.5 mL vials or 10 single-dose 0.5 mL prefilled disposable syringes
Storage	Refrigerate between 36°F and 46°F (2°C to 8°C) DO NOT FREEZE

ACIP Recommendations [cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm](https://www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm)

VFC Letter https://eziz.org/assets/docs/VFC_Letters/2021/July8Vaxelis.pdf

- Billing Codes**
- CPT code for vaccine: 90697
 - CPT code for administration: 90460, 90461
 - Medi-Cal Fee-For-Service (FFS) administration: 90697 with modifiers –SK (high-risk) and –SL (VFC)
 - ICD-10-CM code (encounter for immunization): Z23

www.aafp.org/family-physician/practice-and-career/getting-paid/coding.html

- Comments**
- Licensed in 2018
 - Three doses of Vaxelis™ constitute a primary immunization course against diphtheria, tetanus, H. influenzae type b invasive disease and poliomyelitis.
 - Vaxelis™ may be used to complete the hepatitis B immunization series.
 - A three-dose series of Vaxelis™ does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.
 - Vaxelis™ may be used for the first three doses of the IPV series but is not indicated for the fourth dose.
 - Should not be used for fourth or fifth dose of DTaP series.

